Header Logo

LAUREN AVERETT BYERS

TitleAssistant Professor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, Byers LA, Rudin CM, Shrestha Y. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115. PMID: 38811992; PMCID: PMC11137956.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Yang Y, Wang T, Wang B, Poteete A, Nilsson MB, Le X, Tina C, Jaffray D, Navin N, Byers LA, Gibbons D, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST: Comparing and Contrasting Spatial Transcriptomics data sets using graph contrastive learning. Res Sq. 2024 May 20. PMID: 38826463; PMCID: PMC11142361.
      Citations:    
    3. Aminu M, Hong L, Vokes N, Schmidt ST, Saad M, Zhu B, Le X, Tina C, Sheshadri A, Wang B, Jaffray D, Futreal A, Lee JJ, Byers LA, Gibbons D, Heymach J, Chen K, Cheng C, Zhang J, Wu J. Joint multi-omics discriminant analysis with consistent representation learning using PANDA. Res Sq. 2024 May 17. PMID: 38798352; PMCID: PMC11118856.
      Citations:    
    4. Park S, Hong TH, Hwang S, Heeke S, Gay CM, Kim J, Jung HA, Sun JM, Ahn JS, Ahn MJ, Cho JH, Choi YS, Kim J, Shim YM, Kim HK, Byers LA, Heymach JV, Choi YL, Lee SH, Park K. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. EBioMedicine. 2024 Apr; 102:105062. PMID: 38492534; PMCID: PMC10959651.
      Citations: 1     Fields:    Translation:Humans
    5. Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, Rost S, McGinnis LM, Koeppen H, Gay CM, Minna JD, Heymach JV, Chan JM, Rudin CM, Byers LA, Liu SV, Reck M, Shames DS, Gayevskiy V. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024 Mar 11; 42(3):429-443.e4. PMID: 38366589.
      Citations: 4     Fields:    Translation:Humans
    6. Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horv?th I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024 02 12; 42(2):225-237.e5. PMID: 38278149; PMCID: PMC10982990.
      Citations: 1     Fields:    Translation:HumansCells
    7. Wang Z, Fang Y, Liu Z, Hao N, Zhang HH, Sun X, Que J, Ding H. Adapting Nanopore Sequencing Basecalling Models for Modification Detection via Incremental Learning and Anomaly Detection. bioRxiv. 2023 Dec 20. PMID: 38187611; PMCID: PMC10769248.
      Citations:    
    8. Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic?Targets. JTO Clin Res Rep. 2024 Feb; 5(2):100623. PMID: 38357092; PMCID: PMC10864847.
      Citations:    
    9. Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol. 2023; 14:1322818. PMID: 38152395; PMCID: PMC10751952.
      Citations:    Fields:    Translation:Humans
    10. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506. PMID: 38012986.
      Citations:    Fields:    Translation:Humans
    11. Liu SV, Mok TSK, Nabet BY, Mansfield AS, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair MJ, Garassino MC, Gay CM, Heymach JV, Byers LA, Lam S, Cardona A, Morris S, Adler L, Shames DS, Reck M. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418. PMID: 37931445.
      Citations:    Fields:    Translation:Humans
    12. Zhou D, Byers LA, Sable B, Smit MD, Sadraei NH, Dutta S, Upreti VV. Clinical Pharmacology Profile of AMG?119, the First Chimeric Antigen Receptor?T (CAR-T) Cell Therapy Targeting Delta-Like Ligand?3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC). J Clin Pharmacol. 2024 03; 64(3):362-370. PMID: 37694295.
      Citations: 1     Fields:    Translation:Humans
    13. Megyesfalvi Z, Heeke S, Drapkin BJ, Solta A, Kovacs I, Boettiger K, Horvath L, Ernhofer B, Fillinger J, Renyi-Vamos F, Aigner C, Schelch K, Lang C, Marko-Varga G, Gay CM, Byers LA, Morris BB, Heymach JV, Van Loo P, Hirsch FR, Dome B. Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies. Cancer Cell. 2023 09 11; 41(9):1535-1540. PMID: 37699331; PMCID: PMC11161203.
      Citations: 1     Fields:    Translation:Humans
    14. Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, Cardnell RJ, Wang J, Polanska UM, Andersen C, Saeh J, Pease JE, Travers J, Fabbri G, Gay CM, Urosevic J, Byers LA. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer. Clin Cancer Res. 2023 08 15; 29(16):3237-3249. PMID: 37289191; PMCID: PMC10527398.
      Citations: 2     Fields:    Translation:HumansCells
    15. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023 Nov-Dec; 73(6):620-652. PMID: 37329269.
      Citations: 18     Fields:    Translation:Humans
    16. Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Novel therapeutic strategies for recurrent SCLC. Crit Rev Oncol Hematol. 2023 Jun; 186:104017. PMID: 37150311.
      Citations: 1     Fields:    Translation:Humans
    17. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604. PMID: 36928818; PMCID: PMC10033402.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    18. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19. PMID: 36801912; PMCID: PMC9938883.
      Citations:    
    19. Concannon K, Morris BB, Gay CM, Byers LA. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell. 2023 03 02; 83(5):660-680. PMID: 36669489; PMCID: PMC9992136.
      Citations: 3     Fields:    Translation:HumansCells
    20. Della Corte CM, Ciaramella V, Ramkumar K, Vicidomini G, Fiorelli A, Nardone V, Cappabianca S, Cozzolino I, Zito Marino F, Di Guida G, Wang Q, Cardnell R, Gay CM, Ciardiello D, Martinelli E, Troiani T, Martini G, Napolitano S, Wang J, Byers LA, Ciardiello F, Morgillo F. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. J Transl Med. 2022 11 22; 20(1):541. PMID: 36419183; PMCID: PMC9682755.
      Citations: 2     Fields:    Translation:HumansCells
    21. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 11 03; 27(11):940-951. PMID: 35983951; PMCID: PMC9632312.
      Citations:    
    22. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Dec; 174:112-117. PMID: 36371941.
      Citations:    Fields:    
    23. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6. PMID: 35820397; PMCID: PMC9667883.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    24. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, ICON Team. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform. 2022 07; 6:e2200040. PMID: 35944232; PMCID: PMC9470146.
      Citations:    
    25. Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow CW, Jiang P, Little LD, Gumbs C, Song X, Zhang J, Tan D, Heymach JV, Wistuba I, Futreal PA, Gibbons DL, Byers LA, Zhang J, Reuben A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res. 2022 May 11; 41(1):172. PMID: 35546239; PMCID: PMC9092788.
      Citations:    Fields:    Translation:Humans
    26. Rimner A, Lai WV, Califano R, Jabbour SK, Rudin CM, Faivre-Finn C, Cho BC, Kato T, Yu J, Chafin W, Yu L, Zhao B, Byers L. Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. Clin Lung Cancer. 2022 07; 23(5):e325-e329. PMID: 35613997; PMCID: PMC10905605.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    27. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer. 2022 08; 127(3):569-576. PMID: 35440668; PMCID: PMC9346119.
      Citations:    Fields:    
    28. Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Wang J, Byers L, Della Corte CM, Fasano M, Ciaramella V, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. J Exp Clin Cancer Res. 2022 Mar 26; 41(1):109. PMID: 35346313; PMCID: PMC8962159.
      Citations:    Fields:    Translation:HumansCells
    29. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655. PMID: 34789716; PMCID: PMC8599854.
      Citations: 3     Fields:    Translation:HumansCells
    30. Kundu K, Cardnell RJ, Zhang B, Shen L, Stewart CA, Ramkumar K, Cargill KR, Wang J, Gay CM, Byers LA. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Transl Lung Cancer Res. 2021 Nov; 10(11):4095-4105. PMID: 35004241; PMCID: PMC8674596.
      Citations:    
    31. Cargill KR, Hasken WL, Gay CM, Byers LA. Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. Front Oncol. 2021; 11:757323. PMID: 34745994; PMCID: PMC8566922.
      Citations: 3     
    32. Cargill KR, Stewart CA, Park EM, Ramkumar K, Gay CM, Cardnell RJ, Wang Q, Diao L, Shen L, Fan YH, Chan WK, Lorenzi PL, Oliver TG, Wang J, Byers LA. Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer Metab. 2021 Sep 23; 9(1):33. PMID: 34556188; PMCID: PMC8461854.
      Citations: 1     
    33. Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R, Syrigos K, Byers LA, Clingan P, Bar J, Vokes EE, Govindan R, Dunbar M, Ansell P, He L, Huang X, Sehgal V, Glasgow J, Bach BA, Mazieres J. Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 11 10; 39(32):3633-3644. PMID: 34436928; PMCID: PMC8577684.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    34. Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer. 2021 11; 125(10):1333-1340. PMID: 34294893; PMCID: PMC8576031.
      Citations: 7     Fields:    Translation:HumansCells
    35. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol. 2021 11; 16(11):1821-1839. PMID: 34274504; PMCID: PMC8282443.
      Citations: 10     Fields:    Translation:HumansCells
    36. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov. 2021 10; 11(10):2506-2523. PMID: 33972311; PMCID: PMC8487926.
      Citations: 12     Fields:    Translation:HumansCells
    37. Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun. 2021 05 10; 12(1):2606. PMID: 33972557; PMCID: PMC8110980.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    38. Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen HJM, Gay CM, Fujimoto J, de Groot P, Dunbar M, Kang K, He L, Sehgal V, Glasgow J, Bach BA, Ellis PM. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Na?ve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clin Cancer Res. 2021 07 15; 27(14):3884-3895. PMID: 33947690.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    39. Byers LA, Navarro A, Schaefer E, Johnson M, Han JY, Bondarenko I, Cicin I, Dragnev KH, Abel A, Wang X, McNeely S, Hynes S, Lin AB, Forster M, ?zg?roglu M. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clin Lung Cancer. 2021 11; 22(6):531-540. PMID: 34034991.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    40. Iommelli F, De Rosa V, Terlizzi C, Fonti R, Camerlingo R, Stoppelli MP, Stewart CA, Byers LA, Piwnica-Worms D, Del Vecchio S. A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors. Cancers (Basel). 2021 Apr 22; 13(9). PMID: 33922104; PMCID: PMC8122511.
      Citations: 2     
    41. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel). 2021 Mar 12; 13(6). PMID: 33809063; PMCID: PMC7998226.
      Citations: 3     
    42. Zhang B, Birer SR, Dvorkin M, Shruti J, Byers L. New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer? Am Soc Clin Oncol Educ Book. 2021 Mar; 41:1-10. PMID: 33979194.
      Citations: 3     Fields:    Translation:Humans
    43. Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021 07; 22(4):313-323.e1. PMID: 33745865; PMCID: PMC8562492.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    44. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514. PMID: 33603241; PMCID: PMC8818318.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    45. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. bioRxiv. 2021 Jan 28. PMID: 32577652; PMCID: PMC7302206.
      Citations:    
    46. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 03 08; 39(3):346-360.e7. PMID: 33482121; PMCID: PMC8143037.
      Citations: 78     Fields:    Translation:HumansAnimalsCells
    47. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 05; 22(3):187-194.e1. PMID: 33583720; PMCID: PMC8637652.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    48. Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Res. 2021 03 01; 81(5):1398-1412. PMID: 33402388; PMCID: PMC8026531.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    49. Huang F, Huffman KE, Wang Z, Wang X, Li K, Cai F, Yang C, Cai L, Shih TS, Zacharias LG, Chung A, Yang Q, Chalishazar MD, Ireland AS, Stewart CA, Cargill K, Girard L, Liu Y, Ni M, Xu J, Wu X, Zhu H, Drapkin B, Byers LA, Oliver TG, Gazdar AF, Minna JD, DeBerardinis RJ. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. J Clin Invest. 2021 01 04; 131(1). PMID: 33079728; PMCID: PMC7773395.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    50. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2021 04; 16(4):583-600. PMID: 33388477; PMCID: PMC11160459.
      Citations: 18     Fields:    Translation:Animals
    51. Coleman N, Zhang B, Byers LA, Yap TA. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer. 2021 03; 124(5):857-859. PMID: 33328609; PMCID: PMC7921443.
      Citations: 7     Fields:    Translation:HumansCells
    52. Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM, Frederick MJ. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells. 2020 12 12; 9(12). PMID: 33322834; PMCID: PMC7764697.
      Citations: 7     Fields:    Translation:HumansCells
    53. Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res. 2021 03; 19(3):485-497. PMID: 33172976; PMCID: PMC7925356.
      Citations: 9     Fields:    Translation:HumansCells
    54. Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res. 2020 11; 98:106445. PMID: 32937250; PMCID: PMC9153129.
      Citations:    Fields:    Translation:Humans
    55. Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020 09 09; 11(1):4520. PMID: 32908154; PMCID: PMC7481212.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    56. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 12; 15(12):1919-1927. PMID: 32916308; PMCID: PMC10600713.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    57. Carroll MR, Ramalingam P, Salvo G, Fujimoto J, Solis Soto LM, Phoolcharoen N, Hillman RT, Cardnell R, Byers L, Frumovitz M. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int J Gynecol Cancer. 2020 09; 30(9):1303-1307. PMID: 32727929; PMCID: PMC8375494.
      Citations: 5     Fields:    Translation:Humans
    58. Hillman RT, Cardnell R, Fujimoto J, Lee WC, Zhang J, Byers LA, Ramalingam P, Leitao M, Swisher E, Futreal PA, Frumovitz M. Comparative genomics of high grade neuroendocrine carcinoma of the cervix. PLoS One. 2020; 15(6):e0234505. PMID: 32544169; PMCID: PMC7297329.
      Citations: 7     Fields:    Translation:Humans
    59. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459. PMID: 32389639.
      Citations: 39     Fields:    Translation:Humans
    60. Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Netw Open. 2020 04 01; 3(4):e203277. PMID: 32320035; PMCID: PMC7177199.
      Citations: 4     Fields:    Translation:Humans
    61. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 04; 1:423-436. PMID: 33521652; PMCID: PMC7842382.
      Citations: 52     Translation:HumansCells
    62. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol. 2020 05; 15(5):777-791. PMID: 32068166; PMCID: PMC7202130.
      Citations: 28     Fields:    Translation:Humans
    63. Poirier JT, George J, Owonikoko TK, Berns A, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG, Brambilla E. New Approaches to SCLC Therapy: From the Laboratory to the Clinic. J Thorac Oncol. 2020 04; 15(4):520-540. PMID: 32018053; PMCID: PMC7263769.
      Citations: 31     Fields:    Translation:Humans
    64. Cristea S, Coles GL, Hornburg D, Gershkovitz M, Arand J, Cao S, Sen T, Williamson SC, Kim JW, Drainas AP, He A, Byers LA, Snyder MP, Sage J, Cam LL, Contrepois K. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. Cancer Res. 2020 03 15; 80(6):1293-1303. PMID: 31969375; PMCID: PMC7073279.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    65. Gay CM, Parseghian CM, Byers LA. This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell. 2020 01 13; 37(1):5-7. PMID: 31951562.
      Citations:    Fields:    Translation:Humans
    66. Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer. 2019 12 16; 7(1):351. PMID: 31843013; PMCID: PMC6915970.
      Citations: 12     Fields:    Translation:HumansCells
    67. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    68. Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, Baik C, Joy AA, Jaime JC, Kolek V, Majem M, Roubec J, Santos ES, Chiang AC, Belani CP, Chiappori A, Patel MR, Bahamon B, Li C, Sheldon-Waniga E, Kong EF, Williams M, Badola S, Shin H, Bedford L, Ecsedy JA, Bryant M, Jones S, Simmons J, Leonard EJ, Ullmann CD, Spigel DR, C14018 study investigators, Chouaid C, Speranza G, Czebe K, Byers L. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. J Thorac Oncol. 2020 02; 15(2):274-287. PMID: 31655296.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    69. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273. PMID: 31605794.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    70. Pacheco JM, Byers LA. Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates? Cancer Discov. 2019 Oct; 9(10):1340-1342. PMID: 31575562.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    71. Chen PH, Cai L, Huffman K, Yang C, Kim J, Faubert B, Boroughs L, Ko B, Sudderth J, McMillan EA, Girard L, Chen D, Peyton M, Shields MD, Yao B, Shames DS, Kim HS, Timmons B, Sekine I, Britt R, Weber S, Byers LA, Heymach JV, Chen J, White MA, Minna JD, Xiao G, DeBerardinis RJ. Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell. 2019 12 05; 76(5):838-851.e5. PMID: 31564558; PMCID: PMC6898782.
      Citations: 46     Fields:    Translation:HumansCells
    72. Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. J Thorac Oncol. 2019 12; 14(12):2152-2163. PMID: 31470128; PMCID: PMC7141083.
      Citations: 39     Fields:    Translation:HumansAnimals
    73. Dammert MA, Olsen RR, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretic L, Lorenz C, Jachimowicz RD, Thomas RK, Poirier JT, Sen T, Byers LA, Letai A, Oliver TG, Sos ML, Br?gelmann J, B?hm S, Castiglione R, Wolf E, B?ttner R, Reinhardt HC. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun. 2019 08 02; 10(1):3485. PMID: 31375684; PMCID: PMC6677768.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    74. Gay CM, Byers LA. PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage? J Thorac Oncol. 2019 08; 14(8):1323-1326. PMID: 31345330.
      Citations: 3     Fields:    Translation:Humans
    75. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF. Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019 07; 19(7):415. PMID: 31175338.
      Citations: 5     Fields:    
    76. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel). 2019 May 24; 11(5). PMID: 31137625; PMCID: PMC6562947.
      Citations: 42     
    77. Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ, Pe?a CG. Author Correction: CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature. 2019 May; 569(7756):E4. PMID: 31043737.
      Citations: 1     Fields:    
    78. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019 05; 19(5):289-297. PMID: 30926931; PMCID: PMC6538259.
      Citations: 204     Fields:    Translation:HumansAnimalsCells
    79. Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Sci Transl Med. 2019 03 13; 11(483). PMID: 30867319; PMCID: PMC6878763.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    80. Cardnell RJ, Byers LA, Wang J. Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers. Cancers (Basel). 2019 Feb 19; 11(2). PMID: 30791396; PMCID: PMC6406670.
      Citations:    
    81. Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 05; 9(5):646-661. PMID: 30777870; PMCID: PMC6563834.
      Citations: 202     Fields:    Translation:HumansAnimalsCells
    82. Gay CM, Byers LA, O'Connor MJ, Yap TA, Pili? PG. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res. 2019 07 01; 25(13):3759-3771. PMID: 30760478.
      Citations: 104     Fields:    Translation:HumansAnimals
    83. Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2019 01 29; 10(1):552. PMID: 30696827; PMCID: PMC6351618.
      Citations: 1     Fields:    
    84. Della Corte CM, Gay CM, Byers LA. Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era. Cancer. 2019 02 15; 125(4):496-498. PMID: 30620399; PMCID: PMC6353664.
      Citations:    Fields:    Translation:Humans
    85. Della Corte CM, Byers LA. Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers. Cancer Discov. 2019 01; 9(1):16-18. PMID: 30626603; PMCID: PMC8330553.
      Citations: 8     Fields:    Translation:Humans
    86. Della Corte CM, Gay CM, Byers LA, Morgillo F. ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer. EBioMedicine. 2019 01; 39:5-6. PMID: 30553753; PMCID: PMC6355652.
      Citations: 1     Fields:    Translation:Humans
    87. Pietanza MC, Diao L, Wang J, Byers LA. Reply to F. Liang. J Clin Oncol. 2019 01 20; 37(3):259. PMID: 30496013.
      Citations: 1     Fields:    Translation:Humans
    88. Atrafi F, Groen HJM, Byers LA, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Garralda E, Calles A. A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clin Cancer Res. 2019 01 15; 25(2):496-505. PMID: 30327308.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    89. Hmeljak J, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M, Sanchez-Vega F, Galateau-Sall? F. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565. PMID: 30322867; PMCID: PMC6310008.
      Citations: 169     Fields:    Translation:Humans
    90. Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clin Cancer Res. 2019 01 01; 25(1):346-357. PMID: 30257981; PMCID: PMC6320267.
      Citations: 6     Fields:    Translation:Humans
    91. Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2018 08 06; 9(1):3114. PMID: 30082701; PMCID: PMC6079068.
      Citations: 57     Fields:    Translation:HumansCells
    92. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175. PMID: 30012853; PMCID: PMC6205194.
      Citations: 166     Fields:    Translation:HumansAnimalsCells
    93. Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018 08 10; 36(23):2386-2394. PMID: 29906251; PMCID: PMC6085179.
      Citations: 101     Fields:    Translation:HumansCellsCTClinical Trials
    94. Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci. 2018 Jun; 109(6):1843-1852. PMID: 29624814; PMCID: PMC5989750.
      Citations: 8     Fields:    Translation:HumansCells
    95. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. PMID: 29695765; PMCID: PMC5988803.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    96. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018 04 03; 23(1):194-212.e6. PMID: 29617660; PMCID: PMC6002769.
      Citations: 107     Fields:    Translation:HumansCells
    97. Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck. 2018 08; 40(8):1676-1684. PMID: 29570891; PMCID: PMC6105373.
      Citations: 3     Fields:    Translation:HumansCells
    98. Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018 Mar; 126(3):499-505. PMID: 29398150; PMCID: PMC5856620.
      Citations: 27     Fields:    Translation:HumansCells
    99. Sen T, Gay CM, Byers LA. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Transl Lung Cancer Res. 2018 Feb; 7(1):50-68. PMID: 29535912; PMCID: PMC5835589.
      Citations: 41     
    100. Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 2018 Mar 06; 9(18):14268-14284. PMID: 29581842; PMCID: PMC5865668.
      Citations: 6     Fields:    
    101. Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN. CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res. 2018 02 01; 78(3):781-797. PMID: 29229598; PMCID: PMC5811346.
      Citations: 21     Fields:    Translation:HumansCells
    102. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018 02 15; 124(4):807-815. PMID: 29211313; PMCID: PMC5801102.
      Citations: 62     Fields:    Translation:Humans
    103. Tsao AS, Wistuba I, Xia D, Byers L, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Grigoryev DN, Selvan ME, G?m?s ZH, Tan Z, Zhang S, Nilsson M, Heymach JV. Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precis Oncol. 2017 Nov; 1:1-10. PMID: 35172522.
      Citations: 1     Fields:    
    104. Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 2017 Sep 26; 8(43):73419-73432. PMID: 29088717; PMCID: PMC5650272.
      Citations: 44     Fields:    
    105. Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, Camidge DR. A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. Oncotarget. 2017 Oct 06; 8(46):81441-81454. PMID: 29113403; PMCID: PMC5655298.
      Citations: 4     Fields:    
    106. Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, Heymach JV, Wang J, Byers LA. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clin Cancer Res. 2017 Oct 15; 23(20):6239-6253. PMID: 28698200; PMCID: PMC5882197.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    107. Valenzuela N, Soibam B, Li L, Wang J, Byers LA, Liu Y, Schwartz RJ, Stewart MD. HIRA deficiency in muscle fibers causes hypertrophy and susceptibility to oxidative stress. J Cell Sci. 2017 Aug 01; 130(15):2551-2563. PMID: 28600325.
      Citations: 6     Fields:    Translation:Animals
    108. Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ, Pe?a CG. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature. 2017 06 01; 546(7656):168-172. PMID: 28538732; PMCID: PMC5472349.
      Citations: 106     Fields:    Translation:HumansAnimalsCells
    109. Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017 07 15; 77(14):3870-3884. PMID: 28490518; PMCID: PMC5563854.
      Citations: 75     Fields:    Translation:HumansAnimalsCells
    110. Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res. 2017 Jun 01; 23(11):2713-2722. PMID: 28476872; PMCID: PMC5457365.
      Citations: 42     Fields:    Translation:HumansCells
    111. Kakumu T, Sato M, Goto D, Kato T, Yogo N, Hase T, Morise M, Fukui T, Yokoi K, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. Cancer Sci. 2017 Apr; 108(4):732-743. PMID: 28165654; PMCID: PMC5406588.
      Citations: 7     Fields:    Translation:HumansCells
    112. Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017 Apr 25; 8(17):28575-28587. PMID: 28212573; PMCID: PMC5438673.
      Citations: 71     Fields:    Translation:HumansCells
    113. Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv. 2017 Apr; 3(4):e1600957. PMID: 28439535; PMCID: PMC5397135.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    114. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 06; 7(6):620-629. PMID: 28242752; PMCID: PMC5905335.
      Citations: 155     Fields:    Translation:HumansCellsCTClinical Trials
    115. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017 02 13; 31(2):225-239. PMID: 28196595; PMCID: PMC5501076.
      Citations: 96     Fields:    Translation:HumansCells
    116. Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer. 2017 Feb 14; 116(4):415-423. PMID: 28072762; PMCID: PMC5318970.
      Citations: 105     Fields:    Translation:HumansAnimals
    117. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR, SCRX16-001 investigators. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017 01; 18(1):42-51. PMID: 27932068; PMCID: PMC5481162.
      Citations: 171     Fields:    Translation:HumansCTClinical Trials
    118. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647. PMID: 27480147; PMCID: PMC5065110.
      Citations: 67     Fields:    
    119. Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res. 2017 01; 15(1):45-58. PMID: 27671334; PMCID: PMC5215967.
      Citations: 42     Fields:    Translation:HumansCells
    120. Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology. 2016; 5(11):e1234570. PMID: 27999749; PMCID: PMC5139626.
      Citations: 13     Fields:    
    121. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591]. Gynecol Oncol. 2016 10; 143(1):224. PMID: 27477189; PMCID: PMC5124488.
      Citations:    Fields:    
    122. Lu Y, Ling S, Hegde AM, Byers LA, Coombes K, Mills GB, Akbani R. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol. 2016 08; 43(4):476-83. PMID: 27663479; PMCID: PMC5111873.
      Citations: 24     Fields:    Translation:Humans
    123. Tong P, Diao L, Shen L, Li L, Heymach JV, Girard L, Minna JD, Coombes KR, Byers LA, Wang J. Selecting Reliable mRNA Expression Measurements Across Platforms Improves Downstream Analysis. Cancer Inform. 2016; 15:81-9. PMID: 27199546; PMCID: PMC4863871.
      Citations: 2     
    124. Levin PA, Brekken RA, Byers LA, Heymach JV, Gerber DE. Axl Receptor Axis: A New Therapeutic Target in Lung?Cancer. J Thorac Oncol. 2016 08; 11(8):1357-1362. PMID: 27130831; PMCID: PMC4961571.
      Citations: 16     Fields:    Translation:Humans
    125. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol. 2016 06; 141(3):588-591. PMID: 27079212; PMCID: PMC4877250.
      Citations: 17     Fields:    Translation:Humans
    126. Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. PLoS One. 2016; 11(4):e0152584. PMID: 27055253; PMCID: PMC4824499.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    127. Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4643-50. PMID: 27036135; PMCID: PMC5061056.
      Citations: 27     Fields:    Translation:HumansCells
    128. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 07 15; 22(14):3630-42. PMID: 26851185; PMCID: PMC4947453.
      Citations: 206     Fields:    Translation:HumansCells
    129. Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74. PMID: 26829312; PMCID: PMC4836290.
      Citations: 70     Fields:    Translation:HumansAnimals
    130. Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget. 2016 Jan 05; 7(1):565-79. PMID: 26623721; PMCID: PMC4808018.
      Citations: 15     Fields:    Translation:HumansCells
    131. Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686. PMID: 26597303; PMCID: PMC4818738.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    132. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016 Feb 01; 22(3):609-20. PMID: 26420858; PMCID: PMC4737991.
      Citations: 203     Fields:    Translation:HumansCells
    133. Stewart CA, Byers LA. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition. Cancer Cell. 2015 Jul 13; 28(1):4-6. PMID: 26175409; PMCID: PMC5497474.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    134. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77. PMID: 26069186; PMCID: PMC4527963.
      Citations: 330     Fields:    Translation:HumansCells
    135. Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015 May 15; 21(10):2244-55. PMID: 25979931; PMCID: PMC4497796.
      Citations: 97     Fields:    Translation:HumansAnimals
    136. Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clin Cancer Res. 2015 Aug 01; 21(15):3480-91. PMID: 25878335; PMCID: PMC4526428.
      Citations: 28     Fields:    Translation:HumansCells
    137. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB, St?dler N. Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2015 Jan 28; 6:4852. PMID: 25629879.
      Citations: 4     Fields:    
    138. Tong P, Coombes KR, Johnson FM, Byers LA, Diao L, Liu DD, Lee JJ, Heymach JV, Wang J. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics. 2015 May 15; 31(10):1692-4. PMID: 25600946; PMCID: PMC4426846.
      Citations: 16     Fields:    
    139. Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014 Dec 08; 15:1079. PMID: 25486910; PMCID: PMC4298954.
      Citations: 27     Fields:    Translation:HumansCells
    140. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241. PMID: 25348003; PMCID: PMC4212319.
      Citations: 409     Fields:    Translation:HumansAnimalsCells
    141. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015 Mar 01; 121(5):664-72. PMID: 25336398; PMCID: PMC5497465.
      Citations: 185     Fields:    Translation:Humans
    142. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2738-50. PMID: 25193510; PMCID: PMC4221385.
      Citations: 44     Fields:    Translation:HumansCells
    143. Gibbons DL, Byers LA. A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow. Cancer Discov. 2014 Sep; 4(9):991-4. PMID: 25185188; PMCID: PMC4990388.
      Citations: 5     Fields:    Translation:Humans
    144. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM, Lopez-Bigas N. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014 Aug 14; 158(4):929-944. PMID: 25109877; PMCID: PMC4152462.
      Citations: 630     Fields:    Translation:HumansCells
    145. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31; 511(7511):543-50. PMID: 25079552; PMCID: PMC4231481.
      Citations: 2046     Fields:    Translation:HumansCells
    146. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G, Liang H. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014 Jul; 32(7):644-52. PMID: 24952901; PMCID: PMC4102885.
      Citations: 124     Fields:    Translation:Humans
    147. Garden AS, Gunn GB, Hessel A, Beadle BM, Ahmed S, El-Naggar AK, Fuller CD, Byers LA, Phan J, Frank SJ, Morrison WH, Kies MS, Rosenthal DI, Sturgis EM. Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. Cancer. 2014 Oct 01; 120(19):3082-8. PMID: 24898672; PMCID: PMC4172550.
      Citations: 8     Fields:    Translation:HumansCells
    148. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB, St?dler N. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014 May 29; 5:3887. PMID: 24871328; PMCID: PMC4109726.
      Citations: 248     Fields:    Translation:HumansCells
    149. Cardnell RJ, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--response. Clin Cancer Res. 2014 Apr 15; 20(8):2237. PMID: 24687924; PMCID: PMC4098859.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    150. McGuire MJ, Gray BP, Li S, Cupka D, Byers LA, Wu L, Rezaie S, Liu YH, Pattisapu N, Issac J, Oyama T, Diao L, Heymach JV, Xie XJ, Minna JD, Brown KC. Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. Sci Rep. 2014 Mar 27; 4:4480. PMID: 24670678; PMCID: PMC3967199.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    151. Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck. 2014 Nov; 36(11):1547-54. PMID: 24123531; PMCID: PMC4010580.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    152. Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014 Jan; 12(1):3-13. PMID: 24442106; PMCID: PMC3925633.
      Citations: 98     Fields:    Translation:HumansAnimals
    153. Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014 Mar 15; 120(6):790-8. PMID: 24327434; PMCID: PMC3947683.
      Citations: 25     Fields:    Translation:Humans
    154. Wang J, Byers LA. Teaching an old dog new tricks: drug repositioning in small cell lung cancer. Cancer Discov. 2013 Dec; 3(12):1333-5. PMID: 24327694; PMCID: PMC3878064.
      Citations: 6     Fields:    Translation:HumansAnimals
    155. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6322-8. PMID: 24077350; PMCID: PMC3882158.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    156. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013 Aug; 3(8):870-9. PMID: 23715154; PMCID: PMC3753578.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    157. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90. PMID: 23091115; PMCID: PMC3567921.
      Citations: 463     Fields:    Translation:HumansAnimalsCells
    158. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25. PMID: 22960745; PMCID: PMC3466113.
      Citations: 1742     Fields:    Translation:HumansCells
    159. Park YY, Park ES, Kim SB, Kim SC, Sohn BH, Chu IS, Jeong W, Mills GB, Byers LA, Lee JS. Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One. 2012; 7(9):e44225. PMID: 22970185; PMCID: PMC3436895.
      Citations: 22     Fields:    Translation:HumansCells
    160. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811. PMID: 22961666; PMCID: PMC3567922.
      Citations: 217     Fields:    Translation:HumansCells
    161. James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, You M. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One. 2012; 7(6):e36116. PMID: 22675468; PMCID: PMC3366984.
      Citations: 55     Fields:    Translation:HumansCells
    162. Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, Byers LA, Heymach JV, Girard L, Chiang CM, Teruya-Feldstein J, Scaglioni PP. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 2012 May 01; 72(9):2275-84. PMID: 22406621; PMCID: PMC3342450.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    163. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7(2):e31087. PMID: 22348039; PMCID: PMC3277494.
      Citations: 28     Fields:    Translation:HumansCells
    164. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021; PMCID: PMC3274509.
      Citations: 199     Fields:    Translation:HumansCells
    165. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21. PMID: 21724587; PMCID: PMC3159530.
      Citations: 29     Fields:    Translation:Humans
    166. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, Byers LA, Heymach JV, Story MD, Lee JJ, Sturgis EM, Weber RS, Garden AS, Ang KK, Schwartz DL. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011 Apr 01; 17(7):2035-43. PMID: 21349997; PMCID: PMC3092475.
      Citations: 40     Fields:    Translation:HumansCells
    167. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010 Dec; 5(12):1894-904. PMID: 21124077; PMCID: PMC3374718.
      Citations: 27     Fields:    Translation:HumansCells
    168. Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girard L, Minna JD, Heymach JV, Coombes KR. Blasted cell line names. Cancer Inform. 2010 Oct 14; 9:251-5. PMID: 21082038; PMCID: PMC2978931.
      Citations:    
    169. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010 Aug 15; 70(16):6477-85. PMID: 20663904; PMCID: PMC2922434.
      Citations: 30     Fields:    Translation:HumansCells
    170. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63. PMID: 20530716; PMCID: PMC2913168.
      Citations: 24     Fields:    Translation:HumansCells
    171. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14. PMID: 19917840; PMCID: PMC2799235.
      Citations: 65     Fields:    Translation:HumansCellsCTClinical Trials
    172. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res. 2009 Nov 15; 15(22):6852-61. PMID: 19861436; PMCID: PMC2935176.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    173. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV, J?nne P. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009 May 15; 15(10):3484-94. PMID: 19447865; PMCID: PMC2893040.
      Citations: 125     Fields:    Translation:HumansAnimalsCells
    174. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S79-85. PMID: 17382029.
      Citations: 23     Fields:    Translation:HumansAnimals
    175. Ko N, Averett L, Brown C, Wiener CM. An unexpected finding. Am J Med. 2005 May; 118(5):477-9. PMID: 15866248.
      Citations:    Fields:    Translation:Humans
    176. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003 Feb; 3(2):185-97. PMID: 12620412.
      Citations: 248     Fields:    Translation:Humans
    177. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project, L?pez-Guillermo A. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20; 346(25):1937-47. PMID: 12075054.
      Citations: 1145     Fields:    Translation:Humans
    178. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001; 2(10):RESEARCH0041. PMID: 11597333; PMCID: PMC57796.
      Citations: 158     Fields:    Translation:HumansCells
    179. The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene.
    180. The BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.
    181. Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV-negative head and neck cancer. Clinical Cancer Research. 22:4643-4650.
    182. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer. The Lancet Oncology. 18:42-51.
    183. Axl receptor axis. Journal of Thoracic Oncology. 11:1357-1362.
    184. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head and Neck.
    185. Latent feature decompositions for integrative analysis of diverse high-throughput genomic data. 130-134.
    186. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 1-15.
    187. Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer. PLoS One. 11.
    188. Small cell lung cancer. Clinical Cancer Research. 21:2244-2255.
    189. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecologic Oncology.
    190. Small-cell lung cancer. 143-158.
    191. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591]. Gynecologic Oncology.
    192. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene.
    193. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research. 22:609-620.
    194. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discovery. 5:861-878.
    195. AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers. Molecular Cancer Research. 15:45-58.
    196. Targets by organ site.
    197. Molecular Profiling. 48-66.
    198. Selecting reliable mRNA expression measurements across platforms improves downstream analysis. Cancer Informatics. 15:81-89.
    199. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Seminars in Oncology. 43:476-483.
    200. An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors, including DNA Repair Proteins and Nrf2. Clinical Cancer Research. 21:3480-3491.
    201. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. OncoImmunology.
    202. Giving AXL the axe. British Journal of Cancer.
    203. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research. 22:3630-3642.
    204. Small cell lung cancer. Journal of Thoracic Oncology. 11:453-474.
    205. Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. Clinical Cancer Research. 22:1674-1686.
    206. Corrigendum. Nature Communications. 6.
    207. A HER 1-2 Punch. Cancer Discovery. 4:991-994.
    208. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 15.
    209. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecologic Oncology. 144:46-50.
    BYERS's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (516)
    Explore
    _
    Co-Authors (171)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _